Graphite One

BioTech Stocks

Company
Last Trade
Change
Volume
Shares Out
Market Cap
NASDAQ REGN REGENERON PHARMACEUTICALS
US$ 1.00
14.44 1.36
375,292
108.37M
US$ 116.890B
Follow
NASDAQ MRNA MODERNA
US$ 122.11
1.71 1.42
1.87M
383.24M
US$ 46.800B
Follow
NASDAQ BNTX BIONTECH
US$ 85.94
1.26 1.49
264,743
240.99M
US$ 20.710B
Follow
NASDAQ ROIV ROIVANT SCIENCES
US$ 10.80
0.06 0.56
3.49M
738.72M
US$ 7.980B
Follow
NASDAQ KRYS KRYSTAL BIOTECH
US$ 213.66
2.97 1.41
222,619
28.56M
US$ 6.100B
Follow
NASDAQ BBIO BRIDGEBIO PHARMA
US$ 27.05
0.35 1.31
851,638
187.13M
US$ 5.060B
Follow
NASDAQ NUVL NUVALENT
US$ 81.61
1.66 2.08
148,342
59.12M
US$ 4.820B
Follow
NASDAQ MRUS MERUS
US$ 54.19
-0.13 -0.24
257,130
67.37M
US$ 3.650B
Follow
NASDAQ ACLX ARCELLX
US$ 64.41
1.72 2.74
255,807
53.50M
US$ 3.450B
Follow
NASDAQ KYMR KYMERA THERAPEUTICS
US$ 44.54
0.50 1.14
381,911
61.36M
US$ 2.730B
Follow
NASDAQ CERT CERTARA
US$ 15.72
0.17 1.09
404,788
160.84M
US$ 2.530B
Follow
NASDAQ RXRX RECURSION PHARMACEUTICALS
US$ 8.35
0.30 3.73
2.92M
261.04M
US$ 2.180B
Follow
NASDAQ VERA VERA THERAPEUTICS
US$ 36.70
-0.14 -0.38
416,859
54.70M
US$ 2.010B
Follow
NASDAQ EWTX EDGEWISE THERAPEUTICS
US$ 18.98
0.25 1.33
996,837
93.41M
US$ 1.770B
Follow
NASDAQ BCYC BICYCLE THERAPEUTICS
US$ 24.51
0.07 0.29
79,988
68.73M
US$ 1.680B
Follow
NASDAQ BLTE BELITE BIO
US$ 49.14
0.79 1.63
4,374
29.79M
US$ 1.460B
Follow
NASDAQ SANA SANA BIOTECHNOLOGY
US$ 6.40
0.35 5.79
1.34M
221.50M
US$ 1.420B
Follow
NASDAQ LBPH LONGBOARD PHARMACEUTICALS
US$ 37.40
1.58 4.41
584,165
33.61M
US$ 1.260B
Follow
NASDAQ CNTA CENTESSA PHARMACEUTICALS
US$ 10.78
0.49 4.76
446,635
113.04M
US$ 1.220B
Follow
NASDAQ EQRX EQRX
US$ 2.34
0.00 0.00
0
487.70M
US$ 1.140B
Follow
NASDAQ ABCL ABCELLERA BIOLOGICS
US$ 3.26
0.16 5.16
692,613
294.05M
US$ 958.600M
Follow
NASDAQ HUMA HUMACYTE
US$ 7.94
-0.21 -2.58
3.85M
119.08M
US$ 945.500M
Follow
NYSE NUVB NUVATION BIO
US$ 3.74
0.05 1.36
1.19M
247.17M
US$ 924.420M
Follow
NASDAQ LXRX LEXICON PHARMACEUTICALS
US$ 2.39
0.06 2.58
3.12M
361.49M
US$ 863.960M
Follow
NASDAQ ICVX ICOSAVAX
US$ 15.31
0.00 0.00
0
50.23M
US$ 769.020M
Follow
NASDAQ SAVA CASSAVA SCIENCES
US$ 14.92
2.17 17.02
3.63M
47.98M
US$ 715.860M
Follow
NYSE DNA GINKGO BIOWORKS
US$ 0.37
0.03 9.98
43.55M
1.73B
US$ 640.450M
Follow
NASDAQ CRBP CORBUS PHARMACEUTICALS
US$ 58.06
2.61 4.71
226,885
10.69M
US$ 620.660M
Follow
NASDAQ PEPG PEPGEN
US$ 18.55
0.53 2.94
122,858
32.42M
US$ 601.390M
Follow
NASDAQ HOOK HOOKIPA PHARMA
US$ 6.15
-0.17 -2.69
11,117
96.55M
US$ 593.780M
Follow
NASDAQ TERN TERNS PHARMACEUTICALS
US$ 9.01
0.22 2.50
561,600
64.68M
US$ 582.770M
Follow
NASDAQ AVXL ANAVEX LIFE SCIENCES
US$ 6.74
-0.10 -1.46
1.35M
84.64M
US$ 570.470M
Follow
NASDAQ CMPS COMPASS PATHWAYS
US$ 8.03
0.57 7.64
517,614
68.38M
US$ 549.090M
Follow
NASDAQ ABSI ABSCI
US$ 4.48
0.10 2.28
734,380
113.08M
US$ 506.600M
Follow
NASDAQ NKTX NKARTA
US$ 7.04
0.13 1.88
408,167
70.47M
US$ 496.110M
Follow
NASDAQ ESPR ESPERION THERAPEUTICS
US$ 2.43
0.00 0.00
2.88M
189.46M
US$ 460.390M
Follow
OTCMKTS NWBO NORTHWEST BIOTHERAPEUTICS
US$ 0.38
-0.02 -3.80
384,985
1.21B
US$ 459.800M
Follow
NASDAQ TNYA TENAYA THERAPEUTICS
US$ 3.88
-0.11 -2.76
305,757
78.52M
US$ 304.660M
Follow
NASDAQ DSGN DESIGN THERAPEUTICS
US$ 5.25
0.35 7.14
227,274
56.50M
US$ 296.620M
Follow
NASDAQ PROK PROKIDNEY
US$ 2.45
0.05 2.08
696,726
115.40M
US$ 282.730M
Follow
NASDAQ CDXC CHROMADEX
US$ 3.07
-0.12 -3.76
266,848
75.54M
US$ 231.910M
Follow
OTCMKTS ELTP ELITE PHARMACEUTICALS
US$ 0.19
-0.0004 -0.21
117,043
1.07B
US$ 205.550M
Follow
NASDAQ BMEA BIOMEA FUSION
US$ 5.54
0.08 1.47
312,139
35.94M
US$ 199.110M
Follow
NASDAQ GRPH GRAPHITE BIO
US$ 3.18
0.00 0.00
0
58.24M
US$ 185.200M
Follow
OTCMKTS SKYE SKYE BIOSCIENCE
US$ 6.30
-0.21 -3.23
209,668
28.07M
US$ 176.840M
Follow
NASDAQ RGC REGENCELL BIOSCIENCE
US$ 12.29
3.18 34.91
2.35M
13.01M
US$ 159.890M
Follow
NASDAQ GALT GALECTIN THERAPEUTICS
US$ 2.56
0.01 0.39
52,805
62.15M
US$ 159.100M
Follow
NASDAQ IVVD INVIVYD
US$ 1.32
0.03 2.33
170,598
119.32M
US$ 157.500M
Follow
NASDAQ CRDL CARDIOL THERAPEUTICS
US$ 2.25
0.01 0.45
253,024
69.00M
US$ 155.250M
Follow
NYSEAMEX ZOM ZOMEDICA
US$ 0.15
0.0005 0.33
1.76M
997.95M
US$ 150.190M
Follow
OTCMKTS NGENF NERVGEN PHARMA
US$ 2.06
0.01 0.49
14,906
69.93M
US$ 144.060M
Follow
NASDAQ AMLX AMYLYX PHARMACEUTICALS
US$ 1.97
0.05 2.60
808,253
68.01M
US$ 133.980M
Follow
NASDAQ NVCT NUVECTIS PHARMA
US$ 6.94
0.32 4.83
20,097
18.36M
US$ 127.420M
Follow
NASDAQ DBTX DECIBEL THERAPEUTICS
US$ 4.91
0.00 0.00
0
25.13M
US$ 123.390M
Follow
NYSE ANVS ANNOVIS BIO
US$ 10.96
0.49 4.68
369,445
11.17M
US$ 122.420M
Follow
NASDAQ TALS TALARIS THERAPEUTICS
US$ 2.72
0.00 0.00
0
42.81M
US$ 116.440M
Follow
NASDAQ ADAG ADAGENE
US$ 2.52
-0.01 -0.40
5,787
44.16M
US$ 111.280M
Follow
NASDAQ OMGA OMEGA THERAPEUTICS
US$ 1.92
0.07 3.78
141,660
55.16M
US$ 105.910M
Follow
NASDAQ SNTI SENTI BIOSCIENCES
US$ 2.25
-0.07 -3.02
32,932
45.76M
US$ 102.960M
Follow
NASDAQ ACRS ACLARIS THERAPEUTICS
US$ 1.39
0.04 2.96
402,046
71.26M
US$ 99.050M
Follow
NASDAQ HLVX HILLEVAX
US$ 1.89
0.02 1.07
602,783
49.72M
US$ 93.970M
Follow
OTCMKTS ACOGF ALPHA COGNITION
US$ 0.59
0.07 13.97
75,777
149.93M
US$ 88.460M
Follow
NASDAQ IKNA IKENA ONCOLOGY
US$ 1.70
0.02 1.19
114,302
48.26M
US$ 82.040M
Follow
NASDAQ RANI RANI THERAPEUTICS
US$ 2.93
0.06 2.09
46,910
26.30M
US$ 77.060M
Follow
NASDAQ LABP LANDOS BIOPHARMA
US$ 22.93
0.00 0.00
0
3.13M
US$ 71.770M
Follow
NASDAQ VOR VOR BIOPHARMA
US$ 0.96
0.01 1.09
193,263
68.26M
US$ 65.670M
Follow
NASDAQ IMMX IMMIX BIOPHARMA
US$ 2.24
0.09 4.19
125,042
26.41M
US$ 59.160M
Follow
NASDAQ ANEB ANEBULO PHARMACEUTICALS
US$ 2.20
0.00 0.00
1,482
25.93M
US$ 57.050M
Follow
NASDAQ RLYB RALLYBIO
US$ 1.36
0.03 2.26
46,114
41.45M
US$ 56.370M
Follow
NASDAQ LVTX LAVA THERAPEUTICS
US$ 2.07
-0.04 -1.90
21,726
26.29M
US$ 54.420M
Follow
NASDAQ VTVT VTV THERAPEUTICS
US$ 21.20
0.19 0.90
22,925
2.43M
US$ 51.520M
Follow
NASDAQ RPHM RENEO PHARMACEUTICALS
US$ 1.50
0.01 0.67
78,613
33.42M
US$ 50.130M
Follow
NASDAQ AGLE AEGLEA BIOTHERAPEUTICS
US$ 12.01
0.00 0.00
0
4.05M
US$ 48.640M
Follow
NASDAQ LEXX LEXARIA BIOSCIENCE
US$ 3.38
0.29 9.39
201,411
14.32M
US$ 48.400M
Follow
NASDAQ DYAI DYADIC INTERNATIONAL
US$ 1.55
0.14 9.93
129,804
29.24M
US$ 45.320M
Follow
NASDAQ BNGO BIONANO GENOMICS
US$ 0.63
0.03 4.22
1.02M
69.11M
US$ 43.330M
Follow
NASDAQ AADI AADI BIOSCIENCE
US$ 1.58
-0.03 -1.86
139,021
24.55M
US$ 38.790M
Follow
NASDAQ IXHL INCANNEX HEALTHCARE
US$ 2.17
0.0066 0.31
12,029
17.64M
US$ 38.220M
Follow
OTCMKTS MEDXF MEDEXUS PHARMACEUTICALS
US$ 1.56
0.01 0.65
3,400
24.46M
US$ 38.160M
Follow
NASDAQ INAB IN8BIO
US$ 0.84
0.03 3.22
54,000
44.12M
US$ 37.020M
Follow
NASDAQ IMRX IMMUNEERING
US$ 1.24
0.01 0.81
64,735
29.65M
US$ 36.770M
Follow
NASDAQ QNCX QUINCE THERAPEUTICS
US$ 0.79
0.0057 0.73
38,508
43.22M
US$ 33.960M
Follow
NASDAQ RAIN RAIN ONCOLOGY
US$ 1.21
0.00 0.00
0
27.58M
US$ 33.370M
Follow
NASDAQ RNXT RENOVORX
US$ 1.29
0.06 4.76
16,306
23.95M
US$ 30.860M
Follow
NASDAQ BIAF BIOAFFINITY TECHNOLOGIES
US$ 2.71
0.03 1.12
115,371
11.36M
US$ 30.790M
Follow
NASDAQ PLUR PLUR
US$ 5.65
0.04 0.71
3,736
5.39M
US$ 30.440M
Follow
NASDAQ PMN PROMIS NEUROSCIENCES
US$ 1.60
-0.42 -20.70
6.62M
18.96M
US$ 30.340M
Follow
NASDAQ ANGN ANGION BIOMEDICA
US$ 1.00
0.00 0.00
0
30.11M
US$ 30.110M
Follow
NASDAQ BOLT BOLT BIOTHERAPEUTICS
US$ 0.75
-0.40 -34.78
138,005
38.13M
US$ 28.600M
Follow
NASDAQ ICU SEASTAR MEDICAL
US$ 8.80
0.91 11.53
483,247
3.22M
US$ 28.340M
Follow
NASDAQ LSTA LISATA THERAPEUTICS
US$ 3.39
-0.05 -1.31
3,757
8.31M
US$ 28.130M
Follow
NASDAQ LGVN LONGEVERON
US$ 3.44
0.40 13.16
2.91M
8.12M
US$ 27.930M
Follow
OTCMKTS DTCFF DEFENCE THERAPEUTICS
US$ 0.60
0.00 0.00
0
45.54M
US$ 27.320M
Follow
NASDAQ GANX GAIN THERAPEUTICS
US$ 1.05
0.01 0.96
231,879
25.17M
US$ 26.430M
Follow
NASDAQ BIOR BIORA THERAPEUTICS
US$ 0.67
0.01 1.94
60,742
35.88M
US$ 23.960M
Follow
NASDAQ IPA IMMUNOPRECISE ANTIBODIES
US$ 0.86
0.03 3.12
85,886
26.32M
US$ 22.640M
Follow
NASDAQ OMIC SINGULAR GENOMICS SYSTEMS
US$ 7.80
-0.59 -7.03
11,490
2.47M
US$ 19.270M
Follow
NASDAQ AMRS AMYRIS
US$ 0.05
0.00 0.00
0
369.39M
US$ 18.470M
Follow
NASDAQ LHDX LUCIRA HEALTH
US$ 0.45
0.00 0.00
0
40.60M
US$ 18.360M
Follow
NASDAQ CMMB CHEMOMAB THERAPEUTICS
US$ 1.27
0.08 6.72
196,830
14.22M
US$ 18.060M
Follow
NASDAQ EDSA EDESA BIOTECH
US$ 5.42
0.31 6.07
10,425
3.22M
US$ 17.450M
Follow
NASDAQ SNSE SENSEI BIOTHERAPEUTICS
US$ 0.66
-0.02 -2.64
12,953
25.08M
US$ 16.570M
Follow
NASDAQ GLTO GALECTO
US$ 0.57
0.01 2.36
58,282
27.11M
US$ 15.540M
Follow
NASDAQ AYTU AYTU BIOSCIENCE
US$ 2.70
0.00 0.00
14,618
5.57M
US$ 15.040M
Follow
NYSEAMEX NHWK NIGHTHAWK BIOSCIENCES
US$ 0.41
0.00 0.00
0
36.03M
US$ 14.900M
Follow
NASDAQ BCTX BRIACELL THERAPEUTICS
US$ 0.76
-0.0084 -1.09
85,962
18.28M
US$ 13.920M
Follow
NASDAQ KPRX KIORA PHARMACEUTICALS
US$ 4.70
0.01 0.21
6,743
2.92M
US$ 13.720M
Follow
NASDAQ UPC UNIVERSE PHARMACEUTICALS
US$ 3.74
0.16 4.47
626,806
3.65M
US$ 13.650M
Follow
NASDAQ KTRA KINTARA THERAPEUTICS
US$ 0.24
0.03 12.71
2.31M
55.30M
US$ 13.540M
Follow
NASDAQ RDHL REDHILL BIOPHARMA
US$ 0.40
0.02 4.42
695,289
31.87M
US$ 12.650M
Follow
NASDAQ CHEK CHECK-CAP
US$ 2.01
-0.01 -0.50
3,460
5.85M
US$ 11.760M
Follow
OTCMKTS VPHIF VALEO PHARMA
US$ 0.12
0.00 0.00
0
98.66M
US$ 11.650M
Follow
NASDAQ MBIO MUSTANG BIO
US$ 0.36
0.01 3.18
1.12M
31.42M
US$ 11.330M
Follow
OTCMKTS OTLC ONCOTELIC THERAPEUTICS
US$ 0.03
0.00 0.00
40,000
399.68M
US$ 11.190M
Follow
OTCMKTS HYEX HEALTHY EXTRACTS
US$ 3.77
0.00 0.00
0
2.96M
US$ 11.160M
Follow
NASDAQ MDNA MEDICENNA THERAPEUTICS
US$ 0.16
0.00 0.00
0
69.64M
US$ 10.930M
Follow
NASDAQ IMNN IMUNON
US$ 1.15
-0.02 -1.71
127,079
9.40M
US$ 10.810M
Follow
NASDAQ CDIO CARDIO DIAGNOSTICS
US$ 0.47
0.0022 0.47
186,880
22.69M
US$ 10.620M
Follow
NASDAQ ERNA ETERNA THERAPEUTICS
US$ 1.81
0.01 0.56
4,508
5.41M
US$ 9.790M
Follow
OTCMKTS VYYRF VOYAGEUR PHARMACEUTICALS
US$ 0.07
0.00 0.00
0
138.88M
US$ 9.720M
Follow
NASDAQ COEP COEPTIS THERAPEUTICS
US$ 0.26
-0.0075 -2.80
162,338
37.12M
US$ 9.650M
Follow
OTCMKTS NBIO NASCENT BIOTECH
US$ 0.05
-0.005 -9.09
155,429
172.20M
US$ 8.610M
Follow
OTCMKTS TDSGF TELO GENOMICS
US$ 0.11
0.00 0.00
0
74.56M
US$ 7.930M
Follow
NASDAQ SHPH SHUTTLE PHARMACEUTICALS
US$ 0.44
0.02 5.44
153,972
16.79M
US$ 7.390M
Follow
NASDAQ XBIO XENETIC BIOSCIENCES
US$ 4.28
0.05 1.19
18,594
1.54M
US$ 6.590M
Follow
NASDAQ HUGE FSD PHARMA
US$ 0.15
-0.0031 -2.09
1.18M
43.15M
US$ 6.270M
Follow
NASDAQ JAGX JAGUAR HEALTH
US$ 1.28
-0.07 -5.19
900,705
4.89M
US$ 6.260M
Follow
NASDAQ VIRI VIRIOS THERAPEUTICS
US$ 0.22
-0.01 -5.09
803,001
27.76M
US$ 6.110M
Follow
OTCMKTS SIGY SIGYN THERAPEUTICS
US$ 4.75
0.00 0.00
0
1.26M
US$ 5.980M
Follow
NASDAQ CMND CLEARMIND MEDICINE
US$ 1.79
0.14 8.48
337,930
3.31M
US$ 5.920M
Follow
NASDAQ FRTX FRESH TRACKS THERAPEUTICS
US$ 0.98
0.19 24.05
5,004
5.97M
US$ 5.850M
Follow
NASDAQ IMPL IMPEL PHARMACEUTICALS
US$ 0.24
0.00 0.00
0
23.90M
US$ 5.760M
Follow
NASDAQ SBFM SUNSHINE BIOPHARMA
US$ 0.30
-0.0023 -0.76
408,793
18.95M
US$ 5.690M
Follow
OTCMKTS ODYY ODYSSEY GROUP
US$ 0.06
0.02 38.35
1,455
96.36M
US$ 5.670M
Follow
OTCMKTS TRYPF TRYP THERAPEUTICS
US$ 0.06
0.00 0.00
0
96.42M
US$ 5.420M
Follow
NASDAQ TNXP TONIX PHARMACEUTICALS
US$ 0.55
-0.03 -5.09
1.82M
9.83M
US$ 5.410M
Follow
OTCMKTS BICX BIOCOR RX
US$ 0.55
0.00 0.00
0
9.61M
US$ 5.290M
Follow
NASDAQ KTTA PASITHEA THERAPEUTICS
US$ 5.05
0.39 8.37
2,749
1.04M
US$ 5.250M
Follow
OTCMKTS TBRIF THERMA BRIGHT
US$ 0.01
-0.0023 -16.08
87,000
435.17M
US$ 5.220M
Follow
NASDAQ XRTX XORTX THERAPEUTICS
US$ 1.75
-0.05 -2.78
62,250
2.90M
US$ 5.080M
Follow
OTCMKTS CELZ CREATIVE MEDICAL TECHNOLOGY HOLDINGS
US$ 3.63
0.08 2.11
2,068
1.35M
US$ 4.900M
Follow
NYSEAMEX TOVX THERIVA BIOLOGICS
US$ 0.28
0.04 17.22
47,970
17.28M
US$ 4.790M
Follow
NASDAQ PALI PALISADE BIO
US$ 4.27
0.13 3.02
10,113
936,402
US$ 3.990M
Follow
NASDAQ PRTG PORTAGE BIOTECH
US$ 0.20
-0.0009 -0.46
165,639
19.78M
US$ 3.870M
Follow
NASDAQ ENSC ENSYSCE BIOSCIENCES
US$ 0.43
0.01 3.61
93,431
7.59M
US$ 3.250M
Follow
OTCMKTS RVVTF REVIVE THERAPEUTICS
US$ 0.009
0.00 0.00
0
358.45M
US$ 3.230M
Follow
NASDAQ VRAX VIRAX BIOLABS
US$ 1.37
0.20 17.09
232,664
2.36M
US$ 3.230M
Follow
OTCMKTS AVRW AVENIR WELLNESS
US$ 0.04
0.006 17.65
13,850
79.19M
US$ 3.170M
Follow
OTCMKTS APLIF APPILI THERAPEUTICS
US$ 0.03
0.00 0.00
0
121.27M
US$ 3.030M
Follow
NASDAQ FNCH FINCH THERAPEUTICS
US$ 1.86
0.06 3.33
775
1.61M
US$ 2.990M
Follow
NASDAQ BPTS BIOPHYTIS
US$ 8.22
0.00 0.00
0
286,504
US$ 2.360M
Follow
OTCMKTS AGNPF ALGERNON PHARMACEUTICALS
US$ 0.10
0.00 0.00
0
21.84M
US$ 2.180M
Follow
OTCMKTS AQSZF AEQUUS PHARMACEUTICALS
US$ 0.02
0.00 0.00
0
132.63M
US$ 2.180M
Follow
NASDAQ PXMD PAXMEDICA
US$ 0.28
-0.41 -59.32
95,514
7.78M
US$ 2.180M
Follow
NASDAQ RNAZ TRANSCODE THERAPEUTICS
US$ 0.30
-0.0061 -2.02
872,938
7.27M
US$ 2.150M
Follow
OTCMKTS LOBEF LOBE SCIENCES
US$ 0.01
0.00 0.00
0
164.72M
US$ 1.980M
Follow
NASDAQ NEXI NEXIMMUNE
US$ 1.34
-2.59 -65.90
13,885
1.37M
US$ 1.840M
Follow
OTCMKTS NMLSF NOVA MENTIS LIFE SCIENCES
US$ 0.01
0.00 0.00
0
148.32M
US$ 1.480M
Follow
OTCMKTS MYNDF MYND LIFE SCIENCES
US$ 0.03
0.00 0.00
0
47.82M
US$ 1.430M
Follow
NASDAQ SEEL SEELOS THERAPEUTICS
US$ 0.44
-0.03 -6.60
295,667
2.86M
US$ 1.260M
Follow
NASDAQ CMRA COMERA LIFE SCIENCES
US$ 0.02
0.00 0.00
0
30.74M
US$ 682K
Follow
OTCMKTS PRXTF PURE EXTRACTS
US$ 0.0054
0.00 0.00
0
116.77M
US$ 631K
Follow
NASDAQ CFRX CONTRAFECT
US$ 0.05
0.00 0.00
0
10.70M
US$ 535K
Follow
OTCMKTS BIOAF BIOASIS TECHNOLOGIES
US$ 0.004
0.00 0.00
0
79.41M
US$ 318K
Follow
OTCMKTS TRMNF NEW WAVE HOLDINGS
US$ 0.008
0.00 0.00
0
35.87M
US$ 287K
Follow
NASDAQ EFTR EFFECTOR THERAPEUTICS
US$ 0.05
-0.13 -74.44
11,721
4.70M
US$ 216K
Follow
OTCMKTS SZLSF STAGEZERO LIFE SCIENCES
US$ 0.0015
0.00 0.00
0
123.55M
US$ 185K
Follow
NASDAQ HGEN HUMANIGEN
US$ 0.0002
0.00 0.00
0
119.08M
US$ 24K
Follow
OTCMKTS GDBYF GOODBODY HEALTH
US$ 0.0001
0.00 0.00
0
36.50M
US$ 4K
Follow
NASDAQ EVLO EVELO BIOSCIENCES
US$ 0.0001
0.00 0.00
0
18.98M
US$ 2K
Follow
NASDAQ ALTS ALT5 SIGMA
US$ 2.01
0.01 0.50
44,066
-
US$ -
Follow

BioTech Stock News

Green Stock News

ProMIS Neurosciences Reports Positive Top-Line Data from its Phase 1a Alzheimer's Trial

July 26, 2024

Topline results demonstrated a favorable safety profile and tolerability across four ascending dose levels in healthy volunteers and showed dose dependent levels of PMN310 antibody in Cerebrospinal fluid (CSF) suggestive of its potential for target engagement in Alzheimer’s disease patients CAMBRIDGE, Massachusetts and TORONTO, Ontario, July 26, 2024 (GLOBE NEWSWIRE) -- ProMIS Neurosciences,... Read more

Green Stock News

vTv Therapeutics Announces Cadisegliatin Program for Type 1 Diabetes Placed on Clinical Hold

July 26, 2024

HIGH POINT, N.C., July 26, 2024 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late stage biopharmaceutical company with an innovative clinical portfolio of small molecules and lead program in diabetes, today announced that the United States Food and Drug Administration (FDA) has placed a clinical hold on the cadisegliatin clinical program which includes the ongoing CATT1 Phase 3 trial... Read more

Green Stock News

Nuwellis Announces First Pediatric Patient Treated in a Commercial Setting with SeaStar Medical’s QUELIMMUNE™ Therapy at Cincinnati Children’s

July 26, 2024

MINNEAPOLIS, July 26, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company dedicated to transforming the lives of patients suffering from fluid overload, today announced that the first patient has been treated with the newly launched QUELIMMUNE™ therapy in a commercial setting at Cincinnati Children’s. QUELIMMUNE, manufactured for SeaStar Medical (Nasdaq: ICU)... Read more

Green Stock News

Immix Biopharma: California Institute for Regenerative Medicine Awards Funding for CAR-T NXC-201 U.S. AL Amyloidosis Clinical Trial (NEXICART-2)

July 25, 2024

LOS ANGELES, CA, July 25, 2024 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“ImmixBio”, “Company”, “We” or “Us”, “IMMX”) (Nasdaq: IMMX), a clinical-stage biopharmaceutical company trailblazing cell therapies in AL Amyloidosis and autoimmune disease, today announced that the California Institute for Regenerative Medicine (CIRM) has awarded Immix Biopharma cell therapy division Nexcella... Read more

Green Stock News

Tonix Pharmaceuticals Granted Fast Track Designation by FDA for Tonmya™ for Fibromyalgia

July 25, 2024

Fast Track is designed to expedite FDA review of important new drugs to treat serious conditions and fill an unmet medical need Fast Track designation for Tonmya recognizes fibromyalgia as a serious condition impacting more than 10 million U.S. adults NDA submission on track for second half 2024 Tonmya has the potential to be the first new drug for treating fibromyalgia in more than 15 yea... Read more

Green Stock News

Chemomab Therapeutics Announces Positive Phase 2 Trial Results: CM-101 Achieves Primary and Secondary Endpoints Demonstrating Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Effects in Patients with...

July 25, 2024

First-in-Class CCL24 Neutralizing Antibody CM-101 Demonstrated a Favorable Safety Profile and Was Generally Well-Tolerated Demonstrated Anti-Fibrotic, Anti-Inflammatory and Anti-Cholestatic Activity across Multiple Components of Primary Sclerosing Cholangitis (PSC), Establishing Clinical Proof-of-Concept for the Disease-Modifying Potential of CM-101 Treatment with CM-101 Led to Statistically... Read more

Green Stock News

Ontrak Health Finalizes Study Results for Prominent Health Plan’s Medicaid Members with WholeHealth+ Program

July 25, 2024

$721 PMPM Savings Over 24 Month Period for Graduates $508 PMPM Savings for Non-Graduates MIAMI / Jul 25, 2024 / Business Wire / Ontrak, Inc (NASDAQ: OTRK), a leading AI-powered and technology-enabled behavioral healthcare company, announced the impressive results of a formal evaluation conducted on the Ontrak WholeHealth+ program. The study evaluated the program’s impact on one of its Medicaid... Read more

Green Stock News

Adagene Reports Six Month Financial Results for 2024 and Provides Corporate Update

July 25, 2024

Potential best-in-class therapeutic index for lead candidate anti-CTLA-4 SAFEbody® ADG126 (muzastotug) with higher, more frequent and repeat dosing in combination with Merck’s anti-PD-1 therapy KEYTRUDA* (pembrolizumab) to unleash potential efficacy, while maintaining safety comparable to pembrolizumab alone   Poster planned at European Society of Medical Oncology (ESMO) Congress... Read more

Green Stock News

ALT5 Sigma Reports 99% Year-Over-Year Increase in Transaction Volume to Over US $879 Million for First Two Quarters of 2024

July 25, 2024

LAS VEGAS, NV / ACCESSWIRE / July 25, 2024 / ALT5 Sigma Corporation (NASDAQ:ALTS), a fintech, providing next generation blockchain-powered technologies for tokenization, trading, clearing, settlement, payment, and safe-keeping of digital assets, released its transaction volume for Q1 and Q2 2024 combined. According to the company, ALT5's transaction volume reached US$879 million for the first two... Read more

Green Stock News

Merus Announces First Patient Dosed in LiGeR-HN2, a Phase 3 Trial Evaluating Petosemtamab in 2/3L r/m HNSCC

July 24, 2024

UTRECHT, The Netherlands and CAMBRIDGE, Mass., July 24, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that the first patient has been dosed in the Company’s phase 3 trial evaluating the efficacy and safety of petosemtamab,... Read more

Green Stock News

Nkarta Announces Initiation of Investigator-Sponsored Clinical Trial Evaluating NKX019 for Systemic Lupus Erythematosus

July 24, 2024

SOUTH SAN FRANCISCO, Calif., July 24, 2024 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a biopharmaceutical company developing engineered natural killer (NK) cell therapies, today announced that researchers at Columbia University Irving Medical Center (CUIMC) have initiated an investigator-sponsored trial (“IST”) of NKX019, Nkarta’s allogeneic, CD19-directed chimeric antigen receptor (CAR)... Read more

Green Stock News

Defence Therapeutics Granted CNRI-H from the Canadian Nuclear Laboratories to Accelerate the Development of Its Radio-Immuno-Conjugates Program

July 24, 2024

Vancouver, British Columbia--(Newsfile Corp. - July 24, 2024) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a Canadian biopharmaceutical company developing novel immune-oncology vaccines and drug delivery technologies, is pleased to announce that its Canadian Nuclear Research Initiative Health ("CNRI-H") Program application was retained and approved... Read more

Green Stock News

Creative Medical Technology Initiates Development of AI-Driven Diagnostic and Treatment Program for Biologic and Chemical Exposure Utilizing its Validated iPSC Personalized Medicine Program

July 24, 2024

PHOENIX, July 24, 2024 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (“Creative Medical Technology” or the “Company”) (NASDAQ: CELZ), a leading commercial-stage biotechnology company focused on a regenerative approach to immunotherapy, urology, neurology, and orthopedics, today announced that it has initiated its planned program to diagnose and treat patients exposed to biological... Read more

Green Stock News

ChromaDex Launches Niagen+ NAD+ Test Kit Available Exclusively to Health Care Practitioners (HCPs)

July 23, 2024

Results from the at-home test kit are available to HCPs and their patients through 1health LOS ANGELES / Jul 23, 2024 / Business Wire / ChromaDex Corp. (NASDAQ:CDXC), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, launches the Niagen+ NAD+ Test Kit*, now available exclusively through the company’s healthcare practitioner (HCP) channel.... Read more

Green Stock News

Ensysce Biosciences Provides Mid-Year 2024 Update

July 23, 2024

Ready to Commence PF614 Phase 3 Clinical Trial in 2024  Continued Clinical Development of Overdose Protection Breakthrough Therapy  Identified Lead Clinical Candidate for Opioid Use Disorder Program  SAN DIEGO, CA / ACCESSWIRE / July 23, 2024 / Ensysce Biosciences, Inc. (NASDAQ:ENSC) ("Ensysce" or the "Company"), a clinical-stage pharmaceutical company developing innovative... Read more

Green Stock News

Jaguar Health Reports Phase 3 OnTarget Trial Results for its Cancer Supportive Care Drug Crofelemer

July 23, 2024

Initial results of unprecedented trial including 10 different tumor types indicate that OnTarget did not meet its primary endpoint across all tumor types. Trial did reveal clinically relevant signals for crofelemer in prespecified subgroups of patients with breast and respiratory cancer, including lung cancer. Jaguar to host investor webcast Tuesday, July 23rd at 8:30 AM Eastern to provide updates... Read more

Green Stock News

First Pediatric Patient Treated in a Commercial Setting with SeaStar Medical’s FDA-Approved QUELIMMUNE Therapeutic Device

July 23, 2024

DENVER, July 23, 2024 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU) (SeaStar Medical) reports treatment of the first patient in a commercial setting with QUELIMMUNE™, its U.S. Food and Drug Administration (FDA)-approved, patented cell-directed extracorporeal therapy to treat acute kidney injury (AKI) in pediatric patients weighing 10 kilograms or greater with sepsis or a... Read more

Green Stock News

Bionano Genomics Announces Publication of First Multi-Site Study to Analyze the Utility of OGM in Multiple Myeloma

July 23, 2024

SAN DIEGO, July 23, 2024 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO), today announced the publication of the first multi-site study in multiple myeloma (MM) comparing optical genome mapping (OGM) to traditional cytogenetic methods for the detection of structural variants (SVs). Multiple myeloma is a type of blood cancer originating... Read more

Green Stock News

Virios Therapeutics Announces Completion of Enrollment in IMC-2 Phase 2 Long-COVID Study Being Conducted by Bateman Horne Center

July 23, 2024

Virios projects releasing top line results from this groundbreaking Proof of Concept study in October 2024  Published data indicates increased Epstein-Barr herpes virus in Long-COVID patients, highlighting potential for antiviral therapy to treat fatigue and other Long-COVID symptoms  ATLANTA, July 23, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the ... Read more

Green Stock News

David Rubenstein Joins Moderna's Board of Directors

July 23, 2024

Co-Founder and Co-Chairman of The Carlyle Group brings multi-industry investor experience and global policy expertise, replacing retiring director Stephen Berenson Co-founder and director Robert Langer also to retire from the Moderna Board; recruitment efforts ongoing for his replacement CAMBRIDGE, MA / ACCESSWIRE / July 23, 2024 / Moderna, Inc. (NASDAQ:MRNA) today announced that David M.... Read more

Green Stock News

Nuvalent Announces First Patient Dosed in HEROEX-1 Phase 1a/1b Clinical Trial of NVL-330, its Novel HER2-selective Inhibitor

July 22, 2024

CAMBRIDGE, Mass., July 22, 2024 /PRNewswire/ -- Nuvalent, Inc. (Nasdaq: NUVL), a clinical-stage biopharmaceutical company focused on creating precisely targeted therapies for clinically proven kinase targets in cancer, today announced the initiation of HEROEX-1, its Phase 1a/1b clinical trial evaluating its novel HER2-selective inhibitor, NVL-330, for pre-treated patients with HER2-altered non-small... Read more

Green Stock News

Biophytis Deploys its Partnership Strategy and Signs Two Contracts with Local Agents in Asia

July 22, 2024

PARIS, FRANCE AND CAMBRIDGE, MA / ACCESSWIRE / July 22, 2024 / Biophytis SA (Euronext Growth Paris:ALBPS), ("Biophytis" or the "Company"), a clinical-stage biotechnology company specializing in the development of treatments for age-related diseases, today announces the deployment of its partnership strategy in Asia. To expand its presence in this strategic region, Biophytis has today signed two... Read more

Green Stock News

Shuttle Pharmaceuticals Selective HDAC Inhibitor Exhibits ATM Activation and Modulation of ER Expression Resulting in Substantial Growth Inhibition of Estrogen Receptor Positive Breast Cancer Cells, as...

July 19, 2024

GAITHERSBURG, Md., July 19, 2024 (GLOBE NEWSWIRE) -- Shuttle Pharmaceuticals Holdings, Inc. (Nasdaq: SHPH), (“Shuttle Pharma”), a discovery and development stage specialty pharmaceutical company focused on improving outcomes for cancer patients treated with radiation therapy (RT), today announced the publication of a manuscript reporting on the ability of one of the Company’s HDAC inhibitor... Read more

Green Stock News

Clearmind Medicine Signs an Agreement to Source Manufacturers and Distributors for its Alcohol Substitute Beverage Product

July 19, 2024

Vancouver, Canada, July 19, 2024 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) (“Clearmind” or the "Company"), a clinical-stage biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major under-treated health problems, has announced a strategic engagement with JS First Sdn. Bhd (“JS First”). This partnership aims... Read more

Green Stock News

Palisade Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent for Lead Product Candidate, PALI-2108

July 19, 2024

Patent includes Composition of Matter claims for both PALI-2108 and PALI-1908 programs Patent includes broad claims for “Gut Microbiota Bioactivated PDE4 Inhibitor Precursors” with similar structure to PALI-2108 and PALI-1908 This patent family provides Composition of Matter coverage beyond 2042 PALI-2108 is in development to treat patients with active moderate-to-severely active Ulcerative... Read more

Green Stock News

BriaCell Therapeutics Quadruples Progression Free Survival in Patient with “Eye-Bulging” Metastatic Breast Cancer

July 18, 2024

Progression free survival (PFS) extended to 9.1 months in ADC resistant patient - quadruple the PFS of patients in similar studies 1, 2, 3 Significant reduction of “Eye-Bulging” metastatic breast cancer tumor was previously reported Heavily pre-treated patient had failed 8 prior regimens including antibody-drug conjugate (ADC) therapy and continues to receive BriaCell treatment... Read more

Green Stock News

Haystack Oncology and Lisata Therapeutics Initiate Research Collaboration to Use the Haystack MRD™ Technology to Evaluate Efficacy of Pancreatic Cancer Therapy

July 18, 2024

BALTIMORE, Md. and BASKING RIDGE, N.J., July 18, 2024 (GLOBE NEWSWIRE) -- Haystack Oncology, a Quest Diagnostics (NYSE: DGX) company, and Lisata Therapeutics, Inc. (Nasdaq: LSTA), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of advanced solid tumors and other serious diseases, today announced a research collaboration. Lisata will deploy the highly sensitive... Read more

Green Stock News

Biora Therapeutics Announces Supplemental Data from Phase 1 Clinical Trial of BT-600 as Presented at KOL Event

July 18, 2024

Pharmacokinetic and tissue data confirm NaviCap platform delivers topically through the entire colon, with lower systemic concentrations, as desired Data modeling suggests tofacitinib tissue concentrations greater than IC90 through at least 16 hours after dosing SAN DIEGO, July 18, 2024 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company reimagining therapeutic... Read more

Green Stock News

Pluri’s CDMO Selected to Manufacture Kadimastem’s Novel Cell Therapy Product Candidates

July 18, 2024

HAIFA, Israel, July 18, 2024 (GLOBE NEWSWIRE) -- Leading biotechnology company Pluri Inc. (Nasdaq:PLUR) (TASE:PLUR) ("Pluri" or the "Company"), which transforms cells into solutions that promote global wellbeing and sustainability, today announced it has signed a tech transfer and manufacturing agreement with Kadimastem Ltd. (TASE: KDST), a clinical stage biotechnology company developing therapeutic... Read more

Green Stock News

Positive Interim Body Weight Results from Lexaria Bioscience Diabetes Animal Study

July 17, 2024

DehydraTECH appears to work with a second GLP-1 drug - liraglutide DehydraTECH appears to be working with semaglutide both with and without SNAC technology DehydraTECH-CBD is showing strong apparent performance relative to GLP-1 Dosing in the final four study arms has now begun KELOWNA, BC / ACCESSWIRE / July 17, 2024 / Lexaria Bioscience Corp. (Nasdaq:LEXX, LEXXW) (the "Company"... Read more

COPYRIGHT ©2022 GREEN STOCK NEWS

Research Tools
Stock News
Popular Topics
Miscellaneous